Bifogade filer
PDF
Kurs
+3,73%
Kurs
+3,73%
Open
0,64
High
0,75
Low
0,64
Close
0,69
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
1,02 MNOK
Likviditet
1,02 MNOK
Rel. mcap
1,17%
Antal aktier
1 480 672
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2025-10-10 | - | Extra Bolagsstämma 2025 |
| 2025-08-29 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2025-03-18 | - | Bokslutskommuniké 2024 |
| 2025-01-14 | - | Split OBSRV 15:1 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2024-05-24 | - | Årsstämma |
| 2024-03-13 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Extra Bolagsstämma 2023 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2023-05-26 | - | Årsstämma |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | 15-10 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2022-06-03 | - | Årsstämma |
| 2022-03-29 | - | Bokslutskommuniké 2021 |
| 2022-02-04 | - | Extra Bolagsstämma 2022 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-25 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2021-05-21 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-11-03 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-16 | - | Extra Bolagsstämma 2020 |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-10-22 09:38:29
Oslo, 22 October 2025: Observe Medical ASA (the "Company") has been informed that Glimt Invest AS, a close associate to Terje Bakken, chairman of the board and primary insider of the Company, has purchased 30,000 shares in the Company as further specified in the attached notification form.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.